Public Health Initiatives
To Meaningfully Address the Opioid Crisis, Purdue is Pursuing Three Public Health Initiatives
The Initiatives seek to help individuals suffering from opioid use disorder or overdose by developing and providing millions of doses of three medicines in two categories:
1. Opioid Use Disorder Treatment - one of three FDA approved treatments for opioid dependence, to be used as part of a complete treatment plan that includes counseling and psychosocial support. Purdue is planning to distribute the product to qualified organizations at very low cost to increase access to patients for whom cost may be a barrier to treatment.
2. Opioid Overdose Treatments
a) In July 2023, FDA approved Harm Reduction Therapeutics’ (HRT) new drug application for RiVive™ (Naloxone HCl Nasal Spray 3 mg) to be available over the counter (OTC) for the emergency treatment of opioid overdose. As an independent, non-profit pharmaceutical company, HRT’s mission is to prevent opioid overdose deaths by making low-cost intranasal naloxone available to everyone without a prescription. Since 2018, Purdue has supported HRT’s mission by contributing tens of millions of dollars, extensive technical expertise, and rights to important data to support the development of this opioid overdose reversal medication.
b) Nalmefene HCl injection was approved by the FDA in February 2022 and is available to purchase through Purdue Authorized Distributors. Nalmefene HCl injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and is indicated in the management of known or suspected opioid overdose. Additional delivery formats* and formulations* of Nalmefene HCl are in development.
*These products are not approved by the U.S. Food and Drug Administration, and safety or effectiveness have not been established. There is no guarantee that these products will successfully complete development or gain FDA approval.